RNS Number : 9982X
Alizyme PLC
01 July 2008
For Immediate Release 1 JULY 2008
ALIZYME PLC
ANNUAL INFORMATION UPDATE
Alizyme plc (LSE: AZM), Cambridge, UK, 1 July 2008: Alizyme Annual Information Update for
the period from 1 July 2007 until 30 June
2008.
Alizyme plc ("Alizyme" or the "Company") announces that, in accordance with the
requirements of Prospectus Rule 5.2 issued by the
Financial Services Authority, and following publication of the Annual Report on 22 April 2008,
the following information has been published
or made available to the public during the period from 1 July 2007 until 30 June 2008, in
compliance with laws and rules dealing with the
regulation of securities, issuers of securities and securities markets.
For the purpose of this update, only references to the information are provided. Full
copies of each item can be found at the locations
specified below. The information referred to in this Annual Information Update was correct at
the time it was published but may now be
out-of-date.
1. Announcements made via a Regulatory Information Service
All documents listed below were published via a Regulatory Information Service on the
dates indicated.
Date of publication Title
27 June 2008 Alizyme Licenses COLAL-PRED® to Norgine
24 June 2008 Result of AGM
20 June 2008 Alizyme to present at 2008 Piper Jaffray Europe Conference
12 June 2008 Alizyme to present at the 2008 BIO International Convention
09 June 2008 Notification of Shares
05 June 2008 Notification of Shares
05 June 2008 Notification of Shares
20 May 2008 Interim Management Statement
20 May 2008 Commencement of Phase II Study for COLAL-PRED® in the US
9 May 2008 Major Interest in Shares
02 May 2008 Notification of Shares
30 April 2008 Notification of Shares
29 April 2008 Notification of Shares
23 April 2008 Results from Renzapride
22 April 2008 2007 Annual Report and Accounts & AGM Notification
17 March 2008 Major Interest in Shares
17 March 2008 Major Interest in Shares
17 March 2008 Major Interest in Shares
11 March 2008 Voting Rights and Capital
06 March 2008 Notification of Shareholding
06 March 2008 Cetilistat Phase III Development Plan
06 March 2008 Institutional Placing
06 March 2008 Preliminary Results
19 February 2008 Block Listing
18 February 2008 Major Interest in Shares
01 February 2008 Notification of Shares
25 January 2008 Price Monitoring Extension
24 January 2008 Major Interest in Shares
07 January 2008 Product and Company Update
17 December 2007 Major Interest in Shares
03 December 2007 Voting Rights and Capital
03 December 2007 Strategic Partnership with TSD Japan including a co-development
agreement for COLAL-PRED® in Japan
29 November 2007 Webcast - Alizyme Licenses COLAL-PRED® to Prometheus for North
America
29 November 2007 Alizyme Licenses COLAL-PRED® to Prometheus for North America
07 November 2007 Major Interest in Shares
31 October 2007 Notification of Shares
16 October 2007 Major Interest in Shares
10 October 2007 Phase III Clinical Product Development Update
24 September 2007 Major Interest in Shares
24 September 2007 Major Interest in Shares
16 August 2007 Holding(s) in Company
15 August 2007 Blocklisting
15 August 2007 Blocklisting
24 July 2007 Notification of Shares
19 July 2007 Interim Results
13 July 2007 Notification: Interim Results
02 July 2007 Annual Information Update
Copies of the documents published via a Regulatory Information Service may be obtained
from the Regulatory News Service provided by the
London Stock Exchange (http://www.londonstockexchange.com/en-gb/pricesnews/marketnews/) and
any related documents are available at the UK
Listing Authority's Document Viewing Facility, Financial Services Authority, 25 The North
Colonnade, Canary Wharf, London E14 5HS, UK.
Copies of the documents published via a Regulatory Information Service may also be
obtained from the Company's website at
www.alizyme.com.
2. Documents filed at Companies House
The Company has submitted filings to Companies House in relation to the annual return made
up to 22 February 2008, the annual report and
accounts for the year ended 31 December 2007, the allotment of shares and ordinary and special
resolutions passed at the Company's Annual
General Meeting on 24 June 2008.
Electronic copies of these documents can be purchased from Companies House via its website
at www.companies-house.gov.uk, and hard
copies can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ, UK.
The Company's Annual Report and Accounts 2007 (published on 22 April 2008) and Interim
Report 2007 (published on 19 July 2007) can be
found on the Company's website, as can the Interim Results Announcement for the six months
ended 30 June 2007 (published on 19 July 2007)
and the Preliminary Results for the year ended 31 December 2007 (published on 6 March 2008).The Company's website is www.alizyme.com.
Copies of all documents referred to above are also available for inspection at the
Company's registered office (Granta Park, Great
Abington, Cambridge, CB21 6GX, United Kingdom) during normal business hours or by request from
the Company Secretary.
For further information, please contact:
David Campbell, Company Secretary
ALIZYME plc Tel No: + 44
(0)1223 896000
Further information on Alizyme can be found on the Company's website: www.alizyme.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AIUBGGDRXGGGGIB
|